Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day.
Alpha-glucosidase inhibitor drugs help in the treatment of dumping syndrome and type 2 diabetes. Dumping syndrome is a disease in which the food in the stomach is emptied rapidly into the small intestine. This results in drawing excess of fluid from the partially digested food into the small intestine that causes palpitations, faintness, sweating, diarrhea, cramping, and nausea. Dumping syndrome normally occurs in people who consume excess of refined or simple sugar, specifically in the people who had surgery done to remove or modify the stomach. Type 2 diabetes is also known as insulin resistance due to body cells not being able to respond appropriately in the presence of hormone insulin. It is more complex than type 1 diabetes, however, it is sometimes easier to treat. Undiagnosed type 2 diabetes, may cause severe complications that include coronary artery disease and renal failure.
Growth in geriatric population across the world boosts the demand for alpha-glucosidase inhibitor drugs as elderly people are more prone to diseases such as type 2 diabetes. Furthermore, rising disposable income increases the demand for alpha-glucosidase inhibitor drugs. Sedentary lifestyle of people and changing environmental conditions are the drivers of the global alpha-glucosidase inhibitor drugs market. Moreover, strong inheritable genetic connection in type 2 diabetes propels the market for alpha-glucosidase inhibitor drugs. Increasing cases in obesity and chronic obesity also leads to chances of development of type 2 diabetes, which in turn, drives the growth of the global alpha-glucosidase inhibitor drugs market. Increasing stomach surgeries due to stomach cancer boosts the demand for the alpha-glucosidase inhibitor drugs. According to the World Health Organization (WHO), in 2015, there were 754000 deaths due to stomach cancer.
The global alpha-glucosidase inhibitor drugs market can be segmented on the basis of disease type, distribution channel, and region. Based on disease type, the global alpha-glucosidase inhibitor drugs market can be categorized into dumping syndrome and type 2 diabetes. In terms of the distribution channel, the global alpha-glucosidase inhibitor drugs market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global alpha-glucosidase inhibitor drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America constituted a major share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing prevalence of type 2 diabetes in the region. According to researches, more than 95% of the population in North America is suffering from type 2 diabetes and approximately 20% of this population is over the age of 65. Europe accounted for the next leading share of the alpha-glucosidase inhibitor drugs market in 2016 due to increasing disposable income and high investments in research and development of alpha-glucosidase inhibitor drugs in the region. The alpha-glucosidase inhibitor drugs in Asia Pacific is anticipated to expand during the forecast period owing to increasing awareness about alpha-glucosidase inhibitor drugs, and investments made by key players to penetrate the emerging countries of the region, especially India and China. The alpha-glucosidase inhibitor drugs market in Latin America and Middle East & Africa is also expected to expand during the forecast period owing to increasing government initiatives in the regions.
Key players of the global alpha-glucosidase inhibitor drugs market include Pfizer Inc. and Bayer AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.